SSRI Studies Expose Conflicting Roles for FDA
NPR's Joanne Silberner looks at whether the Food and Drug Administration (FDA) can both ensure public safety and industry confidentiality. The agency has come under tremendous pressure from Congress recently over a class of antidepressant drugs called SSRIs. For months, the FDA had studies questioning the safety and effectiveness of these drugs in children -- but didn't make the studies public until pressured by Congress and the media.
Comments
Discussions for this story are now closed. Please see the Community FAQ for more information.